Curevac starts work on RNA-based drug plant with capacity for Lilly deal

By Gareth Macdonald contact

- Last updated on GMT


Related tags: Boehringer ingelheim, Lilly

Curevac AG has started building a RNA therapeutics plant in Tubingen, Germany.

The plant – known as GMP IV – will be located at Curvac’s headquarters. It is intended for commercial production and will have capacity to make 30 million doses of RNA-based medicines a year when fully operational in 2019.

Curvac said the facility – funds for which will be provided by long-term investor Dietmarr Hopp and other backers – will produce a variety of RNA therapeutics from its pipeline.

The firm added “We will also be well prepared for the needs of our partners’ programs, including our newly established collaboration with Lilly​.”

A Curevac spokeswoman confirm this, telling us "We have four different facilities for GMP production of mRNA. Our Lilly collaboration will have an impact on all four facilities. All facilities will be engaged for delivering of Lilly RNA​."

"The new one is GMP IV bound for an industrial automated process for late stage clinical development and early market supply. For entire market supply we are currently planning for a large scale facility, GMP V​."

She declined to say how much Curevac will spend on GMP IV, but did say "We will create about 60 new jobs only for new facility near-term​."

Plans for GMP IV were announced in 2015 after Curevac secured Gates Foundation funding to develop mRNA vaccines for several unspecified viral, bacterial and parasitic diseases.

Curevac recently completed development of a third manufacturing suite at an existing facility – GMP III – also located at the site.

In addition to Lilly, Janssen, Boehringer Ingelheim and Sanofi Pasteur have all inked multi-million dollar deals with CureVac​.

Related topics: Processing, Delivery technologies, QA/QC

Related news

Related products

show more

How to measure powder and granule flow properties

How to measure powder and granule flow properties

Stable Micro Systems | 01-Apr-2019 | Technical / White Paper

Being able to predict, optimise and control powder flow is of prime importance to manufacturers in ensuring high quality standards. Download this free...

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us


View more